Abstract
Objective Secondary spontaneous pneumothorax (SSP) is traditionally managed with an intercostal chest tube attached to an underwater seal. We investigated whether use of a one-way flutter valve shortened length of patients’ stay (LoS).
Methods This open-label randomised controlled trial enrolled patients presenting with SSP and randomised to either a chest tube and underwater seal (standard care: SC) or ambulatory care (AC) with a flutter valve. The type of flutter valve used depended on whether at randomisation the patient already had a chest tube in place: in those without a chest tube a Pleural Vent (PV) was used; in those with a chest tube in situ, an Atrium Pneumostat (AP) valve was attached. The primary end-point was LoS.
Results Between March 2017 and March 2020, 41 patients underwent randomisation: 20 to SC and 21 to AC (13=PV, 8=AP). There was no difference in LoS in the first 30 days following treatment intervention: AC (median=6 days, IQR 14.5) and SC (median=6 days, IQR 13.3). In patients treated with PV there was a high rate of early treatment failure (6/13; 46%), compared to patients receiving SC (3/20; 15%) (p=0.11) Patients treated with AP had no (0/8 0%) early treatment failures and a median LoS of 1.5 days (IQR 23.8).
Conclusion There was no difference in LoS between ambulatory and standard care. Pleural Vents had high rates of treatment failure and should not be used in SSP. Atrium Pneumostats are a safer alternative, with a trend towards lower LOS
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Walker reports grants from Rocket Medical, during the conduct of the study;.
Conflict of interest: Dr. Keenan has nothing to disclose.
Conflict of interest: Dr. Bintcliffe has nothing to disclose.
Conflict of interest: Dr. Stanton has nothing to disclose.
Conflict of interest: Dr. Roberts has nothing to disclose.
Conflict of interest: Dr. pepperell has nothing to disclose.
Conflict of interest: Dr. Fairbairn has nothing to disclose.
Conflict of interest: Dr. McKeown has nothing to disclose.
Conflict of interest: Dr. Goldring has nothing to disclose.
Conflict of interest: Dr. Maddekar has nothing to disclose.
Conflict of interest: Dr. Walters has nothing to disclose.
Conflict of interest: Dr. West has nothing to disclose.
Conflict of interest: Dr. BHATTA has nothing to disclose.
Conflict of interest: Dr. Knight has nothing to disclose.
Conflict of interest: Dr. Mercer has nothing to disclose.
Conflict of interest: Dr. Hallifax has nothing to disclose.
Conflict of interest: Dr. White has nothing to disclose.
Conflict of interest: Dr. Miller reports personal fees from Gilead, outside the submitted work;.
Conflict of interest: Dr. Rahman reports personal fees from Rocket Medical, outside the submitted work;.
Conflict of interest: Dr. Maskell reports grants from Rocket Medical, during the conduct of the study; personal fees from BD Carefusion, personal fees from Cook Medical, outside the submitted work;.
- Received September 16, 2020.
- Accepted November 30, 2020.
- Copyright ©ERS 2020
LIBRARY USERS
Log in through your institution
Purchase access
